Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...
LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of ...
Ocugen (OCGN) rated Buy as OCU410ST Stargardt trial advances; FDA/EMA alignment speeds path to approval. Read here for more ...
Over the past 60 days, estimates for ANI Pharmaceuticals’ 2025 adjusted EPS have increased from $7.29 to $7.56. Over the same ...
Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to ...
The collaboration will support development of Ascidian's RNA exon editor therapy, ACDN-01, for treating the rare genetic eye disease.
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...
Leqvio (inclisiran) is a prescription drug used to help treat certain types of high cholesterol. Leqvio comes in a prefilled syringe for injection under the skin. Leqvio contains the active drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback